Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection

Journal of Infectious Diseases

Volumn 177, Issue 3, 1998, Pages 539-542

  Thomas, David L ^a   Vlahov, David ^a   Alter, Harvey J ^a   Hunt, Jeffrey C ^a   Marshall, Ronald ^a   Astemborski, Jacquie ^a   Nelson, Kenrad E ^a  

^a 1147 Ross Building ^*

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; CLEARANCE; CONTROLLED STUDY; FEMALE; HEPATITIS G VIRUS; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REINFECTION; VIRUS DETECTION; VIRUS ENVELOPE; VIRUS INFECTION;

EID: 0031887516     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514245     Document Type: Article

References (15)

1. Simons JN, Leary TP, Dawson GJ, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nature Med 1995;1:564-9.
2. Linnen J, Wages J Jr, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996:271:505-8.
3. Alter MJ, Gallagher M, Morris T, et al. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 1997;336:741-6.
4. Alter HJ, Nakatsuji Y, Melpolder JC, et al. The incidence and disease implications of transfusion-associated hepatitis G virus infection. N Engl J Med 1997;336:747-54.
5. Heringlake S, Osterkamp S, Trautwein C, et al. Association between fulminant hepatic failure and a strain of GBV virus C. Lancet 1996;348: 1626-9.
6. Thomas DL, Nakatsuji Y, Shih J, et al. Persistence and clinical significance of hepatitis G virus infections in injecting drug users. J Infect Dis 1997; 176:586-92.
7. Tacke M, Kiyosawa K, Stark K, et al. Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet 1997;349:318-20.
8. Stark K, Bienzle U, Hess G, Engel AM, Hegenscheid B, Schlüter W. Detection of the hepatitis G virus genome among injecting drug users, homosexual and bisexual men, and blood donors. J Infect Dis 1996; 174:1320-3.
9. Masuko K, Mitsui T, Iwano K, et al. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 1996;334: 1485-90.
10. Dille BJ, Surowy TK, Gutierrez RA, et al. An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis 1997;175:458-61.
11. Vlahov D, Anthony JC, Muñoz A, et al. The ALIVE Study: a longitudinal study of IIIV-1 infection in intravenous drug users: description of methods. J Drug Issues 1991;21:759-76.
12. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine 1995;74: 212-20.
13. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Sero-epidemiology of hepatitis B virus in a population of injecting drug users: association with drug injection patterns. Am J Epidemiol 1995; 142:331-41.
14. Muerhoff AS, Simons JN, Leary TP, et al. Sequence heterogeneity within the 5'-terminaI region of the hepatitis GB virus C genome and evidence for genotypes. J Hepatol 1996;25:379-84.
15. Pilot-Matias TJ, Carrick RJ, Coleman PF, et al. Expression of the GB virus C E2 glycoprotein using the semliki forest virus vector system and its utility as a serologic marker. Virology 1996;225:282-92.